Boston Scientific Corp
BSX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$56.00 | Xjwqbpr | Mjwgpzjx |
Boston Scientific: Impressive Farapulse Safety Data Sets High Bar for Competitors
Narrow-moat Boston Scientific's long-awaited clinical data on its Farapulse pulsed field ablation, or PFA, device for atrial fibrillation didn't disappoint, and we've raised our fair value estimate to $55 per share to reflect both our estimates for higher electrophysiology growth, as well as cash flows realized since our last update.